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MicroRNAs (miRNAs) are a family of short, non-coding RNA whose final product is a 
22-nucleotide functional RNA molecule. They regulate the expression of target genes by 
binding to complementary regions of transcripts to repress their translation or promote mRNA 
degradation. Since miRNAs regulate every aspect of cellular function, their dysregulation is 
associated with a variety of diseases including cancer, diabetes, and cardiovascular diseases. 
Therefore, miRNAs are now considered new therapeutic targets. However, the roles of 
miRNAs in the metabolism of xenobiotics and endobiotics have only recently been revealed. 
This review describes the current knowledge on the regulation of cytochrome P450s and 
nuclear receptors by miRNAs, the physiological and clinical significance. The miRNA 
expression is readily altered by chemicals, carcinogens, drugs, hormones, stress, or diseases, 
and the dysregulation of specific miRNAs might lead to changes in the drug metabolism 
potency or pharmacokinetics as well as pathophysiological changes. In the field of 
pharmacogenomics, the evaluation of miRNA-related polymorphisms would provide useful 
information for personalized medicine. Utilizing miRNAs opens a new era in the fields of 
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     MicroRNAs (miRNAs) are short (~22-nucleotide), endogenous non-coding RNAs that 
lead to gene silencing through translational repression or mRNA degradation (Bartel, 2004). 
They are now recognized as critically important regulators of gene expression. So far, more 
than 1000 human miRNAs have been identified (miRBase, release 16, 
http://www.mirbase.org/). Computational prediction estimates that 60% of human mRNAs 
could be targets of miRNAs (Friedman et al., 2009). The miRNAs have roles in fine-tuning 
the expression of their target genes forming intricate networks. Research on miRNA is 
growing exponentially, and it is now clear that miRNAs can potentially regulate every aspect 
of cellular processes such as differentiation, proliferation and apoptosis as well as a large 
range of physiological processes such as development, immune response, metabolism, tumor 
formation, and disease development (Kloosterman and Plasterk, 2006). Since 30% of miRNA 
are expressed in a tissue- or cell-specific manner, the expression patterns are associated with 
the physiological functions of miRNAs. Dysregulation of the miRNA function may lead to 
certain diseases. 
     In the fields of drug metabolism and pharmacokinetics (DMPK), the roles of miRNAs 
have only recently started to become clear. The purpose of this review is to summarize recent 
findings concerning the roles of miRNA in the regulation of cytochrome P450s (P450, CYP) 
and nuclear receptors and their clinical significance with consideration of their potential 
application for pharmacotherapy. 
 
2. Biogenesis of miRNAs and gene regulation by miRNAs 
     Genes encoding miRNA are located in intergenic or intragenic (intronic or exonic) regions 
with both sense and antisense orientations (Lagos-Quintana et al., 2001). In human, the 
distribution of miRNA is as follows: 52% intergenic miRNAs, 43% intronic miRNAs, and 
5% exonic miRNAs (Hinske et al., 2010). The miRNAs are first transcribed as long primary 
transcripts, generating a stem-loop containing primary miRNA (pri-miRNA). The pri-miRNA 
is processed to a 70- to 100-nucleotide hairpin-shaped precursor miRNA (pre-miRNA) by a 
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microprocessor complex including Drosha and DiGeorge syndrome critical region 8 protein 
(DGCR8) in the nucleus. The pre-miRNA is exported into the cytoplasm by Exportin 5, 
processed to miRNA duplex of about 22 nucleotides by Dicer or Ago2, and then unwound 
into the single strand form of mature miRNAs. The functional guide strand is loaded onto the 
RNA-induced silencing complex (RISC), composed of Dicer, TAR RNA binding protein 
(TRBP) and Argonaute protein Ago2, and guides the complex to its mRNA targets with 
imperfect pairing causing translational repression or mRNA degradation (Krol et al., 2010). 
Target sites of animal and human mRNAs are usually at the 3’-untranslated region (UTR), 
although there are examples of target sites in the coding region as well (Duursma et al., 2008). 
The passenger strand, named miRNA*, is usually degraded, although it is sometimes 
functional. Gene silencing by miRNAs include multiple mechanisms and the details can be 
found in other review articles (Chekulaeva and Filipowicz, 2009; Fabian et al., 2010).  
 
3. Prediction/identification of miRNA(s) for a given target gene 
     Identification of miRNA(s) for a target gene is a challenging task because miRNAs bind to 
their target by partial complementarity over a short sequence. The nucleotides 2–8 at the 
5’-end of the miRNA, called the seed sequence, are critical and sometimes sufficient to 
repress the target translation (Lewis et al., 2005). To predict the miRNAs for the target genes, 
several computational programs such as MicroCosm Targets (John et al., 2004), TargetScan 
(Lewis et al., 2003; 2005), Pictar (Krek et al., 2005), and microrna.org (Betel et al., 2008) are 
available. In most cases, many kinds of miRNAs are predicted. The predicted miRNAs vary 
significantly depending on the different algorithms used in the programs, because these 
algorithms place variable weight on complementarity to the miRNA seed sequence, 
evolutionary conservation of the microRNA recognition element (MRE) of the target gene, 
free energy of the miRNA-mRNA duplex, and accessibility of the target site. The false 
positive rate of the predicted candidate targets of a given miRNA is thought to be 30-50% 
(Alexiou et al., 2009; Watanabe et al., 2007). Confirming experimentally the validity of all of 
them is a time-, money, and energy-consuming process. We consider the following points to 
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choose miRNAs that are to be experimentally verified: 1) convergence of algorithms and 2) 
conservation of the target site sequence among species, although these points are neither a 
necessity nor a guarantee of function, 3) accessibility to target: it seems to be a critical feature 
of miRNA target recognition, and 4) whether the miRNA is substantially expressed in the 
tissue where the target mRNA is expressed. 
     To validate specific miRNA:mRNA interaction, several lines of experiments can be used. 
The most commonly employed technology is the use of luciferase assays using reporter 
constructs containing the MRE of the target mRNA downstream of the reporter gene. The 
constructs are co-transfected into the cells with precursor miRNA (or the expression plasmid 
of miRNA) or antisense oligonucleotide (AsO) for miRNA to overexpress or inhibit miRNA. 
Evidence can be established whether the reporter activity is significantly decreased or 
increased. The overexpression or inhibition of miRNA is an effective method to determine 
potential miRNA:mRNA interactions. In the overexpression experiments, a possible concern 
is that the decrease of target expression might be an artifact of overexpression. From this 
point, experiments to inhibit endogenous miRNA are valuable. Furthermore, an inverse 
relationship between the protein and miRNA levels is expected, for example, cancer versus 
normal tissues, or among individuals or cell lines. 
    In addition to the above direct methods, it is useful to determine the change of mRNA or 
protein expression by microarray or proteome analysis after the overexpression or inhibition 
of miRNA to determine the targets of a given miRNA comprehensively  (Lim et al., 2005; 
Baek et al., 2008). It should be noted that these include secondary targets, the expression of 
which may change owing to the expression changes of the primary targets. We should also 
pay attention to the fact that different proteins have different turnover rates. This means that 
the level of protein with high turnover will change rapidly, whereas stable proteins will be 
affected later. In addition, if one determines only the changes in mRNA levels, some targets 
whose expression repression is caused by translational repression could be missed. Thus, for 
comprehensive analysis, both mRNA and protein analysis should be considered. Another 
method is immunoprecipitation of RISC and sequence analysis of mRNAs in the 
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immunoprecipitant (Beitzinger et al., 2007). In such a experiment, we don’t know which 
mRNAs are targets of which miRNA. To overcome this problem, the overexpression or 
inhibition of miRNA before the immunoprecipitation and comparison with control by 
microarray analysis will be useful (Karginov et al., 2007; Chi et al., 2009). 
 
4. miRNAs that regulate P450s and nuclear receptors 
     P450s are important enzymes that catalyze the metabolism of xenobiotics including drugs, 
environmental chemicals, and carcinogens as well as endobiotics such as steroids, bile acids, 
and fatty acids. Most P450s are transcriptionally regulated by nuclear receptors. The 
understanding of the mechanisms of the transcriptional regulation of P450s has progressed 
greatly, but post-transcriptional regulation largely remains to be clarified. Recently, some 
P450s and nuclear receptors have been found to be post-transcriptionally regulated by 
miRNAs (Table 1, Fig. 1). We introduce the examples that have been confirmed as targets of 
miRNA by direct experimental methods as described above, and the clinical significance. 
 
4.1 Relationship to cancer 
     miRNA studies have achieved much progress in the field of cancer. There are many 
publications concerning miRNAs related to cancer. The miRNA expression in most types of 
cancer cells is quite different from that in normal cells. Certain miRNAs have been found to 
serve as oncogenes or tumor suppressor genes, being associated with cancer initiation and/or 
progression. P450s are also one of the factors associated with the initiation or progression of 
cancer. In cancer tissues, some P450 expressions are modulated, and that would lead to an 
imbalance in the metabolism of exo/endobiotics. Some P450s related to cancer have been 
found to be regulated by miRNA as follows. 
 
4.1.1 CYP1B1 
     CYP1B1 catalyzes the metabolic activation of a variety of procarcinogens and 
promutagens, including polycyclic aromatic hydrocarbons and aryl amines (Shimada et at., 
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1996). In addition, CYP1B1 metabolizes 17β-estradiol to form a catechol metabolite that 
cause DNA damage (Han and Liehr, 1994). It has been demonstrated that the expression level 
of CYP1B1 protein is higher in various types of cancer compared with normal tissue (Murray 
et al., 1997), whereas there is no difference in the CYP1B1 mRNA levels between cancerous 
and normal tissues (Cheung et al., 1999) implying post-transcriptional regulation. This 
background prompted us to investigate the possibility that human CYP1B1 might be 
regulated by miRNA, and we found that it is negatively regulated by miR-27b via 
translational repression (Tsuchiya et al., 2006). Interestingly, the expression level of miR-27b 
was lower in breast cancer tissues than in adjacent normal tissues. A significant inverse 
association was observed in the expression levels of miR-27b and CYP1B1 protein between 
breast cancer and normal tissues. The decreased expression of miR-27b would be one of the 
causes of the high expression of CYP1B1 protein in cancer tissues. The study by Tsuchiya et 
al (2006) is the first to reveal the regulation of P450 by miRNA.  
 
4.1.2 CYP2A3 
     Kalscheuer et al (2008) have reported that chronic administration of 
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) to F344 rats reduced the expression 
of several miRNAs including miR-126* in lung. They found that CYP2A3, which catalyzes 
the metabolic activation of NNK, is regulated by miR-126*. Since the reduced miR-126* 
expression was accompanied by increased CYP2A3 expression (at both mRNA and protein 
levels) in the NNK-treated rats, they concluded that the expression changes would reinforce 
NNK genotoxicity.  
 
4.1.3 CYP24 and vitamin D receptor (VDR) 
    1,25-Dihydroxyvitamin D3 (calcitriol) has now received much interest for its anti-tumor 
activity (Deeb et al., 2007), although it is well known as a regulator of calcium and bone 
homeostasis. Most of the biological effects of calcitriol are elicited by the binding to VDR 
(Carlberg and Polly, 1998). Calcitriol is then inactivated by CYP24, a key metabolic enzyme, 
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the expression of which is regulated by VDR (Chen and DeLuca, 1995). It has been reported 
that CYP24 (Deeb et al., 2007) and VDR (Friedrich et al., 2002; Khadzkou et al., 2006) are 
overexpressed in various cancers. We found that both human CYP24 (Komagata et al., 2009) 
and VDR (Mohri et al., 2009) are post-transcriptionally regulated by miR-125b. It was 
demonstrated that the miR-125b expression is decreased in breast cancer tissues, being a 
causal factor of the overexpression of CYP24 and VDR. Since CYP24 is a target of VDR, the 
miR-125b would directly and indirectly regulate CYP24. The increase of VDR in cancer 
tissues would augment the anti-tumor effects of calcitriol, whereas the increase of CYP24 
would attenuate the anti-tumor effects. When we investigated the effects of miR-125b on the 
anti-proliferative effects of calcitriol using human breast cancer-derived MCF-7 cells, the 
overexpression of miR-125b restored the cell growth suppressed by calcitriol, indicating that 
miR-125b had a great impact on the VDR function in this cell system. 
 
4.1.4 Estrogen receptor α (ERα) 
     Three fourths of diagnosed breast cancers express ERα, which is a target of estrogen, 
exerting proliferative effects. ERα is an important marker for the prognosis and is predictive 
of the response to endocrine therapy in breast cancer patients. ERα regulates the expression of 
human CYP1B1, which catalyzes the metabolism of estradiol to a carcinogenic metabolite, 
4-hydroxyestradiol (Tsuchiya et al., 2004). It has been demonstrated that human ERα is 
regulated by miR-206, whereas the activation of ERα results in the decreased expression of 
miR-206, showing mutually inhibitory regulation (Adams et al., 2007). After this report, it 
was reported that miR-221, miR-222 (Zhao et al., 2008), and miR-22 (Xiong et al., 2010) also 
regulate human ERα expression. The authors suggested the possibility that these miRNAs 
may be potential targets for anti-estrogen therapy. 
 
4.2 Relationship to metabolism of xenobiotics/endobiotics 
4.2.1 CYP2E1 
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    CYP2E1 catalyzes the metabolism of a variety of low molecular-weight xenobiotics 
including drugs, organic solvent, and procarcinogens. CYP2E1 is inducible by some 
compounds through post-transcriptional or post-translational mechanisms. In a panel of 
human liver samples, no positive correlation between the CYP2E1 activity and CYP2E1 
mRNA levels was observed (Sumida et al., 1999), indicating the post-transcriptional 
regulation for the constitutive expression. As for the molecular mechanism, we found that 
human CYP2E1 is regulated by miR-378 (Mohri et al., 2010). The significance of miR-378 in 
the regulation of CYP2E1 was supported by the finding of an inverse correlation between the 
miR-378 level and CYP2E1 protein level in a panel of human liver samples. This study could 
provide a new insight into the unsolved mechanism of the post-transcriptional regulation of 
CYP2E1. 
 
4.2.2 CYP3A4 and pregnane X receptor (PXR) 
     CYP3A4 is the most abundant P450 in human liver, and it is responsible for the 
metabolism of more than one half of prescription drugs and endogenous compounds such as 
steroids. There are large interindividual differences (~50 fold) in the CYP3A4 expression 
level in human livers. CYP3A4 is inducible by a wide variety of exogenous and endogenous 
compounds through the activation of PXR, possibly being responsible for the variability in the 
expression levels. We studied whether CYP3A4 and PXR may be regulated by miRNA 
focusing on miR-148a among the various predicted miRNAs, because miR-148a was 
commonly predicted and is substantially expressed in liver. Another reason was that miRNA 
tends to regulate genes in the same pathway to exert its biological function (i.e., miR-148a 
repression of both PXR and CYP3A4 would result in both direct and indirect mechanisms to 
regulate CYP3A4).  
     Our data demonstrated that the miR-148a regulates PXR but not CYP3A4 (Takagi et al., 
2008). Interestingly, the miR-148-dependent regulation of PXR affected the induction of 
endogenous CYP3A4 in human colon carcinoma-derived LS180 cells. Correlation analysis 
using human liver samples showed that the PXR protein level was not positively correlated 
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with PXR mRNA supporting the post-transcriptional regulation. In contrast, the CYP3A4 
protein level showed a significantly positive correlation with the CYP3A4 mRNA level 
indicating that the transcriptional regulation mainly contributes to the expression. Although 
we didn’t examine CYP3A4 further, Pan et al (2009a) subsequently reported that CYP3A4 
protein in LS180 and human pancreas cancer-derived PANC1 cells was decreased by the 
overexpression of miR-27b, accompanied by a decrease of the CYP3A4 mRNA level. A 
limitation of their study may be that the conclusion was drawn from only an overexpression 
study. Again, to determine the impact of miRNAs on their targets, an inhibition study of 
endogenous miRNA as well as correlation analysis between the miRNA and target mRNA 
levels would be necessary. All proteins are produced by mRNA, which means that 
transcriptional regulation certainly participates. The balance between the transcriptional and 
post-transcriptional regulation is critical. If miRNA cannot overcome the strong 
transcriptional regulation of a target gene, the involvement of miRNA may be invisible. We 
think that in CYP3A4 this might be the case. 
     In our study, since the translational efficiency of PXR was inversely correlated with the 
miR-148a levels, it is suggested miR-148a would actually be involved in the regulation of 
PXR in human livers. In addition, the positive correlation between the PXR protein level and 
CYP3A4 at both the mRNA and protein levels suggests that the miR-148a-dependent PXR 
regulation would have great impact on the basal expression of CYP3A4 in human livers. 
     PXR regulates a variety of drug-metabolizing enzymes and transporters. We found that the 
induction of CYP2B6 (2-fold) and multi-drug resistance 1 (MDR1)/P-glycoprotein (5-fold) 
mRNA by rifampicin in LS180 cells was also attenuated by the overexpression of miR-148a. 
Thus, the miR-148a-dependent regulation of PXR appeared to affect target genes in common. 
 
4.2.3 Hepatocyte nuclear factor 4α (HNF4α) and CYP7A 
     HNF4α is a master regulator of drug-metabolizing enzymes, drug transporters, and genes 
involved in the synthesis/metabolism of bile acids, fatty acids, cholesterol, glucose, and urea 
(Gonzalez, 2008). HNF4α regulates gene expression not only via direct binding to the gene’s 
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regulatory sequences but also through the regulation of other transcriptional factors such as 
PXR and constitutive androstane receptor (CAR). HNF4α forms large transcriptional 
regulatory networks in the liver. Therefore, it is believed that the change of HNF4α 
expression has a great impact upon the function of the liver. We found that human HNF4α is 
regulated by miR-24 and miR-34a (Takagi et al., 2010). Interestingly, miR-34a recognizes 
MRE in the 3’-UTR and causes translational repression, whereas miR-24 recognizes MRE in 
the coding region and causes mRNA degradation. The down-regulation of HNF4α by these 
miRNAs resulted in the decrease of various target genes such as CYP7A1, CYP8B1 (bile 
acid-synthesizing enzymes), CYP27A1 (a cholesterol-metabolizing enzyme), and 
phosphoenolpyruvate carboxykinase (PEPCK, a gluconeogenetic enzyme). We also could 
provide a novel feedback loop for bile acid synthesis as follows: bile acids activate protein 
kinase C (PKC)/mitogen-activated protein kinase (MAPK) and reactive oxygen species 
(ROS) pathways. The PKC/MAPK and ROS pathways increase miR-24 and miR-34a 
expression, respectively. These miRNAs down-regulate the HNF4α expression resulting in 
the expression of bile acid-synthesizing enzymes. Thus, the involvement of miRNAs in the 
fine-tuning of bile acid synthesis was demonstrated. 
 
4.3 Others 
     Several research groups (Karbiener et al., 2009; Lin et al., 2009; Jennewein et al., 2010; 
Kim et al., 2010) have reported that miR-27a and miR-27b repress the expression of 
peroxisome proliferator-activated receptor γ (PPARγ) suggesting an association with the 
change in adipocyte differentiation and anti-inflammatory effects. In addition, a recent study 
reported that adipogenesis-regulated miR-130 represses PPARγ, thereby controlling adipocyte 
gene expression programs (Lee et al., 2010). Interestingly, an inverse correlation was 
observed in which PPARγ mRNA was high in obese women but low in lean women, whereas 
miR-130 was low in obese women but high in lean women. Since it was reported that PPARγ 
agonists such as rosiglitazone and pioglitazone increased the expression of CYP26 (retinoic 
acid-metabolic enzyme) in HepG2 cells (Tay et al., 2010), it would be interesting and worth 
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investigating whether the miRNA-dependent regulation of PPARγ affects retinoid 
metabolism. 
     Lin et al (2009) have reported, using mouse embryonic fibroblast-derived 3T3-L1 
preadipocytes, that overexpression of miR-27a or miR-27b decreased the expression of 
C/EBPα, which is involved in the regulation of some P450s (Akiyama and Gonzalez, 2003). 
Pan et al (2009a) have reported, using LS180 and PANC1 cells, that overexpression of 
miR-27b decreased the expression of VDR. Ji et al (2009) have reported, using rat hepatic 
stellate cells, that the inhibition of miR-27a and miR-27b increased the expression of retinoid 
X receptor α (RXRα), a heterodimer partner of various nuclear receptors such as PXR, VDR, 
CAR, PPAR, farnesoid X receptor, and liver X receptor. They described that the sequences of 
MRE on the RXRα mRNA are highly conserved, implying that human RXRα may also be 
regulated by miR-27. Taken together, miR-27 seems to regulate a wide variety of key 
transcriptional factors that are involved in the regulation of various drug metabolizing 
enzymes. It would be interesting to investigate the impact of miR-27 on the metabolism of 
xenobiotics/endobiotics in human livers, in addition to our finding that CYP1B1 is a direct 
target of miR-27b. 
     Vreugdenhil et al (2009) have reported that rat and human glucocorticoid receptors (GR) 
are regulated by miR-18 and miR-124a. Uchida et al (2009) also reported that rat GR is 
regulated by miR-18 and that the sequences of MRE are well conserved among rat, mouse, 
and human. Although the expression of miR-124a is restricted to brain, miR-18 is widely 
expressed throughout the body. Since GR is involved in the regulation of CYP2B6, CYP2C9, 
CYP3A4, PXR, and CAR (Rezen et al., 2011), additional studies are needed to determine 
whether the miRNA-dependent regulation of GR might affect drug metabolism. 
     Collectively, it has been revealed that various nuclear receptors are regulated by miRNAs. 
The regulation of nuclear receptors by miRNA results in changes in the expression of a 
variety of target genes, constructing complex regulatory networks. Since this knowledge has 
only recently been taken into consideration in drug metabolism, further studies are warranted 
to clarify the clinical significance of miRNAs in the control of pharmacokinetics for better 
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understanding of inter- and intraindividual differences in drug responses and adverse 
reactions. 
 
5. Modulation of miRNA expression 
 
5.1 Modulation of miRNA expression by chemicals, drugs, and hormones 
     Similar to coding RNA, miRNAs are controlled by transcription factors (Krol et al., 2010). 
There are several reports regarding the changes of miRNA expression through 
ligand-activated nuclear receptors. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), a potent 
environmental toxicant, is a ligand of aryl hydrocarbon receptor (AhR), which forms a 
heterodimer with AhR nuclear translocator (ARNT) and binds to xenobiotic response 
elements on the promoter of many kinds of drug-metabolizing enzymes such as CYP1A, 
alcohol dehydrogenase (ALDH), and glutathione S-transferase (GST). It is well known that 
TCDD causes vast changes in mRNA expression, but the administration of TCDD to mice 
and rats caused few changes in miRNA (45 and 17 miRNAs, respectively) levels in liver 
(Moffat et al., 2007). Mouse and rat hepatoma cells in culture also exhibited few changes in 
miRNAs in response to TCDD (Moffat et al., 2007). A recent study has reported that the oral 
administration of benzo(a)pyrene, another ligand of AhR, to mice caused no changes in 
miRNA, in spite of widespread changes (> 400 genes) in mRNA expression (Yauk et al., 
2010). 
     It has been demonstrated that the administration of Wy-14,643, a specific PPARα agonist, 
to mice for 2 weeks caused changes (>1.5-fold) in the expression of 27 miRNAs (12 miRNAs 
were decreased and 15 miRNAs were increased) (Shah et al., 2007), but greater changes in 
707 mRNAs (671 mRNAs were decreased and 36 mRNAs were increased, >4-fold). When rat 
primary thymocytes were treated with dexamethasone, a synthetic glucocorticoid that binds to 
GR, the expression of 56 out of 350 miRNAs was altered (44 miRNAs were decreased and 12 
miRNAs were increased) (Smith et al., 2010). Testosterone, which regulates gene expression 
through androgen receptor (AR), affects the expression of 6 miRNAs in female mouse liver 
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(Delić et al., 2010). Treatment of estradiol, a ligand of ERα, caused changes in the expression 
of a subset of miRNAs in mice, rats, and human breast cancer-derived MCF-7 cells (Klinge, 
2009). Taken together, the expression of miRNAs actually changes in response to chemicals 
and steroid hormones, but the changes are likely smaller than those of mRNA expression. 
     Various stressors also affect miRNA expression. Arsenite, which is known to activate 
nuclear factor-erythroid 2-related factor 2 (Nrf2) (Aono et al., 2003), affects miRNA 
expression in human lymphoblastoid TH-6 cells (Marsit et al., 2006). Cigarette smoking 
causes the down-regulation of many miRNAs in the lungs of both mice and rats (Izzotti et al., 
2011) as well as human airway epithelial cells (Schembri et al., 2009). The administration of 
the hepatotoxicants acetaminophen or carbon tetrachloride to rats caused changes in the 
expression of some miRNAs (there were only 13 commonly changed miRNAs in the two 
groups) in liver (Fukushima et al., 2007). As described above, the chronic administration of 
NNK, a tobacco-specific carcinogen, to rats reduced the expression of several miRNAs in 
lung (Kalscheuer et al., 2008). There is accumulating evidence that these up-regulated or 
down-regulated specific miRNAs could alter the expression of target mRNAs and lead to 
some phenotypic changes (Shah et al., 2007; Kalscheuer et al., 2008; Maillot et al., 2009; 
Ribas et al., 2009). 
     Interestingly, it has been demonstrated that enoxacin, an antibiotic, affects the processing 
of miRNAs by facilitating the interaction between TRBP and RNA (Shan et al., 2008). 
Yamagata et al (2009) reported that the ligand-activated ERα inhibits the Drosha processing 
of pre-miRNA. Smith et al (2010) have reported that the expression of miRNA-processing 
enzymes such as Dicer, Drosha, and DGCR8 were significantly reduced at the mRNA and 
protein levels during glucocorticoid-induced apoptosis. Thus, it is likely that chemicals and 
steroids modulate the expression of miRNAs not only transcriptionally but also 
post-transcriptionally.  
    
5.2 Modulation of miRNA expression in disease 
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     A growing number of reports have shown that aberrant miRNA expression is a common 
feature of human diseases such as cancer, Alzheimer’s disease, cardiovascular disease, 
schizophrenia. Since miRNAs regulate cellular functions, it is not surprising that miRNAs are 
implicated in a wide variety of diseases. We can refer to a database for miRNA-diseases 
associations, the Human MiRNA & Disease Database (HMDD) 
(http://202.38.126.151/hmdd/mirna/md/) (Lu et al., 2008). Because of the growing evidence 
that a variety of diseases are associated with the dysregulation of miRNAs, miRNAs are now 
considered as a new tool for diagnosis and therapy, as described below in detail (Calin and 
Croce, 2006). Our great concern is that such dysregulation of specific miRNAs in diseases or 
miRNA manipulation in therapy may lead to changes in drug responses in patients, although 
it has never been noticed so far. 
 
6. Potential therapeutic applications of miRNAs 
 Since miRNAs are differently expressed in diseases and they play critical roles in various 
biological pathways, miRNAs are expected to be potential targets of therapeutics. The 
modulation of the levels of miRNAs can be adapted from existing gene therapy and antisense 
technology. For miRNAs whose expression is reduced in diseases, re-introduction of miRNA 
into the proper tissue could provide a therapeutic benefit by restoring the regulation of target 
gene(s). An RNA-interference-based method using chemically modified antagomirs or locked 
nucleic acid (LNA)-modified oligonucleotides is already being developed. The therapeutic 
potency has been demonstrated in vivo using experimental animals such as mouse and 
monkey (Krützfeldt et al., 2005; Lanford et al., 2010). Furthermore, there are several ongoing 
clinical trials (Seto et al., 2010; Wahid et al., 2010). The most advanced miRNA-based 
therapeutics is targeted to the liver-specific miR-122, which is involved in hepatitis C 
replication and cholesterol metabolism. The company reported that there have been no 
apparent adverse reactions so far. In addition, some pioneering pharmaceutical companies 
have initiated studies on creating therapeutic candidates with miRNA mimics or miRNA 
inhibitors for cancer, cardiovascular diseases, neurological disorders, and viral infections. It is 
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possible that the miRNA-based therapy could be used to regulate drug sensitivity. For 
example, the expression changes of miRNA in cancer cells are associated with resistance to 
anti-cancer drugs (Saker et al., 2010), and there is accumulating evidence that many drug 
transporters such as MDR1/P-glycoprotein, breast cancer resistance protein (BCRP/ABCG2), 
and multi-drug resistance-associated protein 1 (MRP1) are regulated by miRNAs (Zhu et al., 
2008; Pan et al., 2009b, Liang et al., 2010). It is also possible that miRNAs could be utilized 
to selectively modulate drug metabolizing enzymes, drug transporters, and nuclear receptors 
toward optimal drug responses in pharmacotherapy. Targeting miRNAs for therapy could be 
an emerging field, although there are many hurdles to be overcome: stability, appropriate in 
vivo delivery systems, and selectivity. An individual miRNA could regulate several genes and 
pathways simultaneously suggesting that miRNA modulation could be powerful. However, 
attention must be paid to the possibility that miRNA manipulation may cause unanticipated 
effects, because the targets of the each miRNA have not been thoroughly clarified. 
 
7. miRNA-related polymorphisms 
     Single nucleotide polymorphisms (SNPs) are the most common human genetic variants. 
The SNPs may affect either the expression or activities of various enzymes, and therefore 
may be associated with differences in the physiological or pharmacological outcomes. 
Polymorphisms can be present not only in the mRNA but also in mature miRNA sequences. 
In addition, polymorphisms in pri-miRNA and pre-miRNAs affect the expression level of 
mature miRNAs (Iwai et al., 2005; Duan et al., 2007) and might lead to modification of the 
expression level of target genes. A polymorphism in an mRNA target site would be 
target-specific, whereas a polymorphism in an miRNA may affect the expressions of multiple 
genes and have serious consequences. A polymorphism in the genes encoding 
miRNA-processing enzymes may have a large impact (Horikawa et al., 2008). 
     Thousands of miRNA-related polymorphisms have been identified and are catalogued in 
databases such as Patrocles (http://www.patrocles.org/Patrocles.htm) and PolymiRTS 
(http://compbio.uthsc.edu/miRSNP/). Many miRNA-related polymorphisms have been shown 
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to be associated with diseases (Sethupathy and Collins, 2008), because a gain-of function or 
loss-of-function of miRNA polymorphisms would result in changes in the expression of target 
mRNAs that are related to diseases: e.g., SLITRK1 (Slit and Trk-like 1) 
gene/miR-189/Tourette’s syndrome, AGTR1 (angiotensin receptor 1) 
gene/miR-155/hypertension, and FGF20 (fibroblast growth factor 20) 
gene/miR-433/Parkinson disease. 
     Pharmacogenetics research has matured considerably during the past few decades. The 
importance and implications of genetic polymorphisms in genes encoding drug metabolizing 
enzymes are largely recognized. Representative polymorphisms that can be used clinically are 
these of UDP-glucuronosyltransferase/irinotecan and thiopurine methyltransferase/thiopurines. 
In contrast to the accumulating evidence of polymorphisms on coding genes that affect drug 
responses and adverse effects, there are few examples regarding miRNA-related 
polymorphisms that can affect drug responses. A SNP in the binding site of miR-24 in the 
3’-UTR of human dihydrofolate reductase gene leads to the overexpression of dihydrofolate 
reductase and methotrexate resistance (Mishra et al., 2007). Interestingly, it has been reported 
that SNPs in the pri-miR26a-1 or pri-miR-100 genes were significantly associated with the 
tumor response or time to progression in patients treated with 5-fluorouracil and CPT-11 
(Boni et al., 2011), although the molecular mechanism by which these polymorphisms act is 
not yet understood.  
     Actually, the SNPs exist on the 3’-UTR of many genes encoding P450s and other drug 
metabolizing enzymes. So far, most of them might be overlooked, because they are unlikely 
to affect the enzyme property or expression levels. Further studies are warranted to investigate 
whether the SNP may lose or gain the recognition site of miRNA, causing differences in the 
clinical outcome. Pharmacogenomics research on miRNAs should provide clues to 




     We now recognize the critical roles of miRNAs in numerous physiological processes and 
their involvement in human diseases. There is increasing interest in understanding the 
contribution of miRNAs to pharmacological and toxicological outcomes. How is miRNA 
expression changed under physiological conditions (diet, alcohol, smoking, environmental 
chemicals, stress, supplement, medication, or diseases)? Do the differences in the miRNA 
expression affect the drug response or susceptibility to xenobiotic toxicity? How do the 
miRNA-related polymorphisms affect pharmacokinetics and pharmacodynamics? Clarifying 
such issues will provide us better understanding of the intra- and interindividual variability in 
drug responses. miRNAs have clearly opened a new field in DMPK and toxicology.  
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Table 1. Cytochrome P450s and nuclear receptors that are regulated by miRNAs. 
Target  miRNA   Reference 
CYP1B1  miR-27b   Tsuchiya et al., 2006 
CYP2A3 (rat) miR-126*   Kalscheuer et al., 2008 
CYP2E1  miR-378   Mohri et al., 2010 
CYP3A4  miR-27b   Pan et al., 2009a 
CYP24A1  miR-125b   Komagata et al., 2009 
 
PXR  miR-148a   Takagi et al., 2008 
VDR  miR-125b   Mohri et al., 2009 
PPARγ  miR-27a   Kim et al., 2010, Lin et al., 2009 
miR-27b Karbiener et al., 2009, Jennewein et al., 2010 
  miR-130   Lee et al., 2010 
RXRα (rat) miR-27   Ji et al., 2009 
HNF4α  miR-24a, miR-34  Takagi et al., 2010 
ERα  miR-206   Adams et al., 2007 
  miR-221/222  Zhao et al., 2008 
  miR-22   Xiong et al., 2010 
GR  miR-18, miR-124a  Vreugdenhil et al., 2009 




Fig. 1. Cytochrome P450s and nuclear receptors that are regulated by miRNAs. The miRNAs 
regulate targets forming an intricate network with transcriptional factors and signal 
transduction pathways.  
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